ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Odyssey Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.10+0.93 (+5.42%)
Close on Oct 19, 2026
- Market cap
- $548.01M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.68 (+10.23%)since May 8, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $548.01M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $13.91
- Diluted shares
- 30M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period